The increasing complexity of cancer chemotherapy makes it mandatory that pharmacists be familiar with these highly toxic agents. This column reviews various issues related to the preparation, dispensing, and administration of cancer chemotherapy, both commercially available and investigational.
Get full access to this article
View all access options for this article.
References
1.
WozniakA., CrowleyJ.J., BalcerzakS.P.Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: A southwest oncology group study. J Clin Oncol.1998; 16(7): 2459–65.
2.
KellyK., CrowleyJ., BunnP.A.A randomized phase III trial of paclitaxel plus carboplatin (PC) versus vinorelbine plus cisplatin (VC) in untreated advanced non-small cell lung cancer (NSCLC): A Southwest Oncology Group (SWOG) trial. Proc Am Soc Clin Oncol.1999; 18: 461a.
3.
Le ChevalierT., BrisgandD., DouillardJ.Y.Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: Results of a European multicenter trial including 612 patients. J Clin Oncol.1994; 12(2): 360–7.
BrettiS., BerrutiA., GorzegnoG.Multicenter phase II trial of intermediate dose cisplatin and vinorelbine in inoperable non-small cell lung cancer patients. Lung Cancer.1996; 14: 353–60.
6.
DepierreA., ChastangC.L., QuoixE.Vinorelbine versus vinorelbine plus cisplatin in advanced non-small cell lung cancer: A randomized trial. Ann Oncol.1994; 5: 37–42.
7.
VialletJ., BrassardM.A., SouhamiL.A phase I/II trial of neoadjuvant chemotherapy with cisplatin and vinorelbine followed by accelerated irradiation for patients with inoperable nonsmall cell lung carcinoma. Cancer.1999; 85(12): 2562–9.
8.
FelipE., Del CampoJ.M., BodiR.Cisplatin and vinorelbine followed by radiotherapy in the treatment of stage III-B non-small-cell lung cancer patients. Am J Clin Oncol.1997; 20(4): 404–6.
9.
American Society of Clinical Oncology.Clinical practice guidelines for the treatment of unresectable non-small cell lung cancer. J Clin Oncol.1997; 15(8): 2996–3018.
10.
HeskethP.J., KrisM.G., GrunbergS.M.Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol.1997; 15: 103–9.
11.
American Society of Health-System Pharmacists.ASHP therapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery. Am J Health-Syst Pharm.1999; 56: 729–64.
12.
National Comprehensive Cancer Network.NCCN antiemesis practice guidelines. Oncology.1997; 11: 57–89.
13.
GrallaR.J., OsobaD., KrisM.G.Recommendations for the use of antiemetics: Evidence-based, clinical practice guidelines. J Clin Oncol.1999; 17: 2971–94.
14.
CornelisonT.L., ReedE.Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin. Gynecol Oncol.1993; 50: 147–58.
American Society of Clinical Oncology.American Society of Clinical Oncology recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol.1994; 12: 2471–508.
LymanG.H., KudererN., GreeneJ.The economics of febrile neutropenia: Implications for the use of colony-stimulating factors. Eur J Cancer.1998; 34: 1857–64.
19.
MullinS., BeckwithM.C., TylerL.S.Prevention and management of antineoplastic extravasation injury. Hosp Pharm.2000; 35: 57–74.
20.
HensleyM.L., SchuchterL.M., LindleyC.American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J Clin Oncol.1999; 17: 3333–55.
21.
KintzelP.E., DorrR.T.Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function. Cancer Treat Rev.1995; 21: 33–64.
22.
VempatyH., SrinivasS.Cisplatin in elderly. Proc Am Soc Clin Oncol.1999; 18: 607a.
